Biologic showdown: which IBD drug works best after a year?
NCT ID NCT07495644
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study will follow 95 adults with moderate-to-severe Crohn's disease or ulcerative colitis in Upper Egypt who are taking one of five biologic drugs: adalimumab, infliximab, ustekinumab, golimumab, or vedolizumab. After one year, researchers will measure how many patients avoid hospitalization, surgery, and steroids, and achieve endoscopic remission. The goal is to compare the effectiveness of these treatments in a real-world setting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- adalimumab, infliximab, ustekinumab, golimumab, and vedolizumab (biologic drugs)
- What this could lead to
- If successful, this could show which biologic works best for controlling IBD over a year, helping doctors choose more effective treatments.
- What could go wrong
- This is a small, early-stage study (95 people) in one region, so results may not apply broadly. Biologics also carry risks like serious infections.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLAMATORY BOWEL DISEASE (CROHN'S AND ULCERATIVE COLITIS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.